# PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer

> **NCT02331927** · PHASE2 · UNKNOWN · sponsor: **University of Ulm** · enrollment: 150 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **BIOLOGICAL:** Aflibercept

## Key facts

- **NCT ID:** NCT02331927
- **Lead sponsor:** University of Ulm
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-03
- **Primary completion:** 2020-03
- **Final completion:** 2021-03
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2019-09-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02331927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02331927, "PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02331927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*